Global Fund to Fight AIDS, Tuberculosis & Malaria
$160,000,000.00 CAD
- Department
- Global Affairs Canada
- Recipient country
- Switzerland
- Fiscal year
- 2021-2022
- Agreement period
- December 23, 2021 – December 31, 2023
- Reference
- dfatd-maecd:064-2022-2023-Q4-00009
Published purpose
Canadian funding through this project will enable the Global Fund to procure and deliver about 6,329,000 antigen rapid diagnostic tests (Ag-RDTs) to low-income and lower middle-income countries (LICs & LMIICs), at the current price of US$2.50 per test. Of this amount, 75% would go to most severely-affected countries in Africa, and most of the remainder going to the hardest-hit countries in Asia. These tests represent a significant improvement over lab-based or automated polymerase chain reaction (PCR) tests, which are being used in a number of countries. Compared with PCR tests, which can be expensive and take longer to provide results, these RDTs are low-cost and can provide results in 15 minutes. Improving access to testing is essential for controlling the spread of COVID-19 through enabling targeted public health measures and use of therapeutics and vaccines as they become available and delivered.
In plain English AI-generated
This Canadian funding enables the Global Fund to procure and distribute about 6.3 million rapid diagnostic tests for COVID-19 to low- and lower-middle-income countries, prioritizing African and Asian nations most affected by the pandemic.
Category: Health Primarily funds activity outside Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.